The paper trail

Small print.
Wide open.

A clear path from a claim to the page it came from. Here’s the filing, the research, and how we read it.

The documentS–1Anthropic, PBC26 OCT 2026 · 421 PP.
01The original SEC filingThe authoritative source, in your browser.SEC · HTML 02Download the saved filingThe complete 421-page document, optimized for downloading.PDF · 46 MB 03Download the full researchFindings, customer examples, calculations, and source references.Markdown

Page by page

Go straight to the source.

Page references count physical pages in the saved PDF, starting at 1. The printed filing number is shown separately when available.

Enter a page from 1 to 421. No PDF download needed.

From the filing

PDF page 266

Printed filing page 255 · Extracted page text

View on the SEC
Read the page text
Table of Contents

was  a  Principal  in  the  Private  Equity  Group  at  Blackstone,  a  global  investment  firm,  from  September  2011  to 
September  2015.  Mr.  Rao  began  his  career  as  a  strategy  consultant  at  Bain,  a  global  management  consulting 
firm, from September 2005 to July 2008. Mr. Rao holds a J.D. from Yale Law School and an A.B. in Economics 
from Harvard College.

Non-Employee Directors

Reed Hastings. Mr. Hastings has served as a member of our board of directors since May 2025. Mr. Hastings 
co-founded  Netflix,  a  global  streaming  service,  and  served  as  Netflix’s  Chief  Executive  Officer  and  President 
from 1999 to January 2023, Executive Chairman from January 2023 to April 2025, and Chairman of the board 
from April 2025 to June 2026. Prior to Netflix, Mr. Hastings founded Pure Software, a software development 
tools  company,  in  1991  and  served  as  its  Chief  Executive  Officer  until  its  acquisition  by  Rational  Software  in 
1997.  Mr.  Hastings  currently  serves  on  the  board  of  Bloomberg,  a  financial  data  and  media  company.  Mr. 
Hastings holds an M.S.C.S. in Artificial Intelligence from Stanford University and a B.A. in Mathematics from 
Bowdoin  College.  We  believe  that  Mr.  Hastings  is  qualified  to  serve  as  a  member  of  our  board  of  directors 
because  of  his  extensive  board  experience  at  major  technology  companies,  his  demonstrated  commitment  to 
responsible innovation and its societal impact, his deep understanding of technology’s transformative potential, 
and his philanthropic focus on education and AI’s impact on humanity.

Christopher Liddell. Mr. Liddell has served as a member of our board of directors since February 2026. In 
the private sector, Mr. Liddell has served as the Chief Financial Officer of several public companies, including 
Microsoft and International Paper, and served as Vice Chairman and Chief Financial Officer at General Motors. 
Mr. Liddell has served as a Director of Commonwealth Fusion Systems, a fusion power company, since March 
2025, and as a Director of the Council on Foreign Relations, a nonpartisan U.S. think tank focused on foreign 
policy  and  international  affairs,  since  July  2025.  He  has  also  held  positions  with  the  U.S.  government  from 
January 2017 to January 2021, including serving at the White House as the Deputy Chief of Staff, Director of 
Strategic  Initiatives,  and  as  a  member  of  the  American  Technology  Council.  Mr.  Liddell  holds  a  Master  of 
Philosophy from the University of Oxford and a Bachelor of Engineering from the University of Auckland. We 
believe that Mr. Liddell is qualified to serve as a member of our board of directors because of his wide range of 
experience from his corporate and public service career and his deep expertise in the financial management of 
publicly listed companies.

Vasant “Vas” Narasimhan. Dr. Narasimhan has served as a member of our board of directors since April 
2026.  Dr.  Narasimhan  has  served  as  the  Chief  Executive  Officer  of  Novartis  AG,  a  global  medicine  company, 
since  February  2018.  He  joined  Novartis  in  April  2005  and  has  held  numerous  leadership  roles  across  the 
organization,  including  Global  Head  of  Drug  Development  and  Chief  Medical  Officer  from  February  2016  to 
January 2018 and Global Head of Development from September 2014 to February 2016. Dr. Narasimhan holds 
an M.D. from Harvard Medical School, an M.P.P. from the Harvard Kennedy School, and a B.A. in Biology from 
the  University  of  Chicago.  We  believe  that  Dr.  Narasimhan  is  qualified  to  serve  as  a  member  of  our  board  of 
directors  because  of  his  extensive  experience  leading  a  large  global  public  company  in  a  highly  regulated 
industry and his track record of responsibly stewarding breakthrough science at scale.

Yasmin Razavi. Ms. Razavi has served as a member of our board of directors since March 2023. Ms. Razavi 
joined  Spark  Capital,  a  venture  capital  firm,  in  July  2017  and  has  served  as  a  General  Partner  since  March 
2020. Prior to joining Spark Capital, Ms. Razavi served as an investor at Index Ventures, a venture capital firm, 
from  August  2014  to  August  2015,  and  as  a  consultant  at  McKinsey  &  Company,  a  business  management 
consulting firm, from August 2012 to August 2014. Ms. Razavi holds an M.B.A. from Harvard Business School 
and a Bachelor of Applied Science and Engineering from the University of Toronto. We believe that Ms. Razavi 
is  qualified  to  serve  as  a  member  of  our  board  of  directors  because  of  her  experience  in  venture  capital  and 
growth-stage investing, her deep expertise in enterprise go-to-market strategies, and her understanding of the 
technology sector and scaling high-growth companies.

Family Relationships 

Dario Amodei, our Chief Executive Officer and a member of our board of directors, and Daniela Amodei, our 
President  and  Chairperson  of  our  board  of  directors,  are  siblings.  There  are  no  other  family  relationships 
among any of our executive officers or directors.

255

Text is provided for reference. Check the original for tables, images, and exact formatting.

Find a section 16 starting points

Section links may begin before the exact paragraph cited in a finding. PDF numbers below use physical pages.

  1. Founders’ letterp. 3SEC
  2. Defined termsp. 12SEC
  3. Prospectus summaryp. 16SEC
  4. Risk factorsp. 38SEC
  5. Management’s discussion & analysisp. 144SEC
  6. Businessp. 190SEC
  7. Governancep. 254SEC
  8. Executive compensationp. 275SEC
  9. Related-person transactionsp. 293SEC
  10. Principal & selling stockholdersp. 299SEC
  11. Capital-stock rightsp. 303SEC
  12. Shares eligible for future salep. 318SEC
  13. Underwritingp. 327SEC
  14. Auditor change & expertsp. 345SEC
  15. Financial statements & notesp. 347SEC
  16. Part II & exhibit indexp. 413SEC

How this was made

Read in full.
Kept in context.

A snapshot of the filing dated , rather than a live record of later events.

3primary reviewers
421pages reviewed
43image instances checked

The review

Three primary reviewers read non-overlapping ranges of the complete main filing. All 43 embedded image instances were transcribed and visually reviewed, including the founders’ letter, charts, and customer case studies. Financial tables were also checked visually for dates, units, and column alignment.

A separate reviewer checked the draft’s calculations, accounting interpretations, and customer qualifications. An additional check covered the later merged findings. The result is 62 findings and 21 customer examples.

The boundary

Companion contracts and other exhibits named in the filing’s index are separate documents and were not independently reviewed. Customer outcomes, technical benchmarks, forecasts, and scientific priority claims remain attributed company or customer disclosures.

The numbers

Dollar figures are U.S. dollars. H1 means the six months ended June 30; Q2 means the three months ended June 30. The 2026 interim financial statements are unaudited. Our calculations show their inputs and are labeled separately from reported values.

Blank fields stay undisclosed. Figures with different periods, conditions, or potentially overlapping scopes are kept separate. An earlier tender price is not an IPO price.

What the evidence labels mean
Reported in filing
A company disclosure, with the period and accounting basis retained.
Company estimate / company claim
An estimate or assertion attributed to the company, with its uncertainty preserved.
Our calculation
A derived figure using cited inputs. It is not a separately reported company metric.
Customer example
A selected case study, with its measurement limits. It is not representative ROI.
Proposed / conditional
A status qualifier for an arrangement that is not yet effective or depends on stated conditions.

About updates. This edition is tied to the October 26, 2026 filing. Any later revision should identify its new source date and preserve the basis of earlier claims.

The footnotes are only the beginning.Explore the findings Read the story
The original, in context

Open the footnote.

A closer look at the filing

Anthropic · Form S-1PDF 1

Opening page 1…

Filed October 26, 2026. PDF is approximately 46 MB and opens only when requested. Section links may precede the exact cited paragraph.